Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia

Completed · Not applicable

Conditions studied: Waldenstrom's Macroglobulinemia

In brief

The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.

Key facts

Study ID

NCT00142155

Run by

Dana-Farber Cancer Institute

People needed

300

Starts

2002-01-01

Expected to finish

2007-03-01

Last updated by the study team

2011-06-27

Who can join

Age: 30 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients treated with rituximab or other monoclonal antibodies for Waldenstrom's macroglobulinemia

Where it is running

• Dana-Farber Cancer Institute — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.